1/1
3 files

Supplementary Figures – PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer

figure
posted on 14.02.2022, 16:57 authored by Figshare Future Science GroupFigshare Future Science Group, Rachel Woodford, Deborah Zhou, Sarah J Lord, Ian Marschner, Wendy A Cooper, Craig R Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee

Supplementary Figure S1. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer

Flow diagram showing inclusion and exclusion of studies and trial reference list

Supplementary Figure S2. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer

Impact of PD-L1 expression on progression-free survival. Forest plots display the progression-free survival (PFS) hazard ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size.

Supplementary Figure S3A-B. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer

Impact of PD-L1 expression on overall survival with the exclusion of IMPOWER150 trial and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). Forest plots S3A display the overall survival (OS) hazard ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size.

Forest plots S3B display the objective response rate (ORR) odds ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size.

History